Medicare Price Inflation Rebates In Build Back Better Bill Are Prospective Only
The legislation would also establish new manufacturer discounts in Medicare Part D as part of a redesign of the benefit that includes a cap on beneficiary out-of-pocket spending. Negotiations are still fluid on the overall legislative package, however, and things could change.
You may also be interested in...
The US Association for Accessible Medicines has panned the Biden administration’s Build Back Better Act, which it says threatens patient access to affordable drugs in its current form.
Score of slimmed down Medicare negotiations in the Build Back Better legislation is $79bn, a far cry from the $456bn in savings projected from the draconian HR 3. But the bill’s overall impact on the deficit means that pharma might get a total reprieve – or go back on the chopping block.
Concerns that Medicare drug price negotiation provisions in the Build Back Better legislation would upend the US generic and biosimilar industries might resonate with legislators more than complaints from branded drug companies.